Gene Expression Variability in Human Hepatic Drug Metabolizing Enzymes and Transporters

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Yang, Lun ^a,d   Price, Elvin T ^b   Chang, Ching Wei ^a   Li, Yan ^a   Huang, Ying ^c   Guo, Li Wu ^a   Guo, Yongli ^a   Kaput, Jim ^a,e   Shi, Leming ^a   Ning, Baitang ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^d GLAXOSMITHKLINE   (United States)

^e NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMIODARONE; AMPRENAVIR; BENIDIPINE; CANDESARTAN HEXETIL; CIMETIDINE; CLOPIDOGREL; DESIPRAMINE; DIMEBON; DOMPERIDONE; DRUG METABOLIZING ENZYME; EFAVIRENZ; GLIBENCLAMIDE; INDINAVIR; KETOCONAZOLE; MANIDIPINE; METRONIDAZOLE; MEVINOLIN; OCTREOTIDE; ORPHENADRINE; OXCARBAZEPINE; PHENYTOIN; PROGUANIL; RABEPRAZOLE; RETINOIC ACID; SULCONAZOLE; TEGASEROD; TOREMIFENE; TRIMETHOPRIM; UNINDEXED DRUG; CARRIER PROTEIN; CELL RECEPTOR; DRUG; ENZYME; TRANSCRIPTOME;

ARTICLE; COPY NUMBER VARIATION; DISEASE PREDISPOSITION; DMET GENE; ENVIRONMENTAL FACTOR; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INTERACTION; GENETIC VARIABILITY; HUMAN; MICROARRAY ANALYSIS; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; ENZYMOLOGY; GENE REGULATORY NETWORK; GENETICS; LIVER; METABOLISM; PERSONALIZED MEDICINE;

CARRIER PROTEINS; ENZYMES; GENE REGULATORY NETWORKS; HUMANS; INDIVIDUALIZED MEDICINE; LIVER; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTOME;

EID: 84876541448     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060368     Document Type: Article

References (43)

1. Wilkinson GR, (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352: 2211-2221.
2. Spear BB, Heath-Chiozzi M, Huff J, (2001) Clinical application of pharmacogenetics. Trends Mol Med 7: 201-204.
3. Constable S, Johnson MR, Pirmohamed M, (2006) Pharmacogenetics in clinical practice: considerations for testing. Expert Rev Mol Diagn 6: 193-205.
4. Lazarou J, Pomeranz BH, Corey PN, (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279: 1200-1205.
5. Waxman DJ, Holloway MG, (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76: 215-228.
6. Ma MK, Woo MH, McLeod HL, (2002) Genetic basis of drug metabolism. Am J Health Syst Pharm 59: 2061-2069.
7. Zhou SF, Liu JP, Chowbay B, (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41: 89-295.
8. Rodriguez-Antona C, Donato MT, Pareja E, Gomez-Lechon MJ, Castell JV, (2001) Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 393: 308-315.
9. Guo L, Dial S, Shi L, Branham W, Liu J, et al. (2011) Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes. Drug Metab Dispos 39: 528-538.
10. Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al. (2008) Mapping the genetic architecture of gene expression in human liver. PLoS Biol 6: e107.
11. Yang X, Zhang B, Molony C, Chudin E, Hao K, et al. (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20: 1020-1036.
12. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP, (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423.
13. Ning B, Dial S, Sun Y, Wang J, Yang J, et al. (2008) Systematic and simultaneous gene profiling of 84 drug-metabolizing genes in primary human hepatocytes. J Biomol Screen 13: 194-201.
14. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, et al. (1999) Housekeeping genes as internal standards: use and limits. J Biotechnol 75: 291-295.
15. Horvath S, Dong J, (2008) Geometric interpretation of gene coexpression network analysis. PLoS Comput Biol 4: e1000117.
16. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabasi AL, (2002) Hierarchical organization of modularity in metabolic networks. Science 297: 1551-1555.
17. Amaral LA, Scala A, Barthelemy M, Stanley HE, (2000) Classes of small-world networks. Proc Natl Acad Sci U S A 97: 11149-11152.
18. Owens IS, Basu NK, Banerjee R, (2005) UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol 400: 1-22.
19. Ning B, Nowell S, Sweeney C, Ambrosone CB, Williams S, et al. (2005) Common genetic polymorphisms in the 5′-flanking region of the SULT1A1 gene: haplotypes and their association with platelet enzymatic activity. Pharmacogenet Genomics 15: 465-473.
20. Ning B, Wang C, Morel F, Nowell S, Ratnasinghe DL, et al. (2004) Human glutathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form. Pharmacogenetics 14: 35-44.
21. Li D, Liu Z, Cui Y, Li W, Fang H, et al. (2011) Toxicity of cyanobacterial bloom extracts from Taihu Lake on mouse, Mus musculus. Ecotoxicology 20: 1018-1025.
22. Liguori MJ, Anderson MG, Bukofzer S, McKim J, Pregenzer JF, et al. (2005) Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41: 177-186.
23. Pirmohamed M, Park BK, (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 22: 298-305.
24. Zanger UM, Turpeinen M, Klein K, Schwab M, (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392: 1093-1108.
25. Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, et al. (2002) CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 71: 196-204.
26. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ, (2004) CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 93: 104-107.
27. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
28. Hagenbuch B, (2010) Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol Ther 87: 39-47.
29. Ieiri I, Higuchi S, Sugiyama Y, (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5: 703-729.
30. Kroetz DL, Yee SW, Giacomini KM, (2010) The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther 87: 109-116.
31. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J, (2008) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8: 4-15.
32. Daniel WC, Lange RA, Landau C, Willard JE, Hillis LD, (1996) Effects of the intracoronary infusion of cocaine on coronary arterial dimensions and blood flow in humans. Am J Cardiol 78: 288-291.
33. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP, (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45: 177-202.
34. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther.
35. Yang L, Li Y, Hong H, Chang C, Guo LW, et al. (2012) Sex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver. J Drug Metab Toxicol 3: 1-9.
36. Chrostek L, Jelski W, Szmitkowski M, Puchalski Z, (2003) Gender-related differences in hepatic activity of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in humans. J Clin Lab Anal 17: 93-96.
37. Wauthier V, Verbeeck RK, Calderon PB, (2007) The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem 14: 745-757.
38. Novembre J, Johnson T, Bryc K, Kutalik Z, Boyko AR, et al. (2008) Genes mirror geography within Europe. Nature 456: 98-101.
39. Tirona RG, Kim RB, (2005) Nuclear receptors and drug disposition gene regulation. J Pharm Sci 94: 1169-1186.
40. Omiecinski CJ, Vanden Heuvel JP, Perdew GH, Peters JM, (2011) Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci 120Suppl 1: S49-75.
41. Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M, (2005) A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem 386: 503-513.
42. Tolson AH, Wang H, (2010) Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62: 1238-1249.
43. Shay NF, Banz WJ, (2005) Regulation of gene transcription by botanicals: novel regulatory mechanisms. Annu Rev Nutr 25: 297-315.